Title
Regional and state-level patterns of type 2 diabetes prevalence in Mexico over the last three decades
Date Issued
01 July 2021
Access level
metadata only access
Resource Type
journal article
Author(s)
Seiglie J.A.
Franco R.R.
Wirtz V.J.
Meigs J.B.
Mendoza M.A.
Gómez-Dantés H.
Lozano R.
Wexler D.J.
Serván-Mori E.
CRÓNICAS, Centro de Excelencia en Enfermedades Crónicas
Publisher(s)
Elsevier Ireland Ltd
Abstract
Aims: We aimed to characterize and illustrate the regional and state-level change in type 2 diabetes (T2D) prevalence in Mexico between 1990 and 2017. Methods: We conducted an ecological and secondary analysis using data from the Global Burden of Disease study on T2D prevalence of the adult Mexican population. We estimated the absolute increase and annual growth rate of T2D prevalence between 1990 and 2017, stratified by age group and region. Results: Nationally, between 1990 and 2017, the prevalence of T2D in Mexico increased from 9.5% to 14.3%. The highest increase in T2D prevalence was observed in the East and Southcentral regions, with the lowest absolute change in T2D prevalence observed in Northern states. The highest average annual growth rate in T2D prevalence was observed in Southern Mexico, in the three Southern states with the lowest human development index, and among individuals ages 15–49 years across all regions, compared to those 50 years and older. Conclusions: The prevalence of T2D in Mexico has increased substantially over the past three decades, with a clear shift in T2D prevalence from Northern to Southern states and a faster increase occurring in Southern Mexico among younger adults and in areas with lower economic resources.
Volume
177
Language
English
OCDE Knowledge area
Políticas de salud, Servicios de salud
Subjects
Scopus EID
2-s2.0-85109447516
PubMed ID
Source
Diabetes Research and Clinical Practice
ISSN of the container
01688227
Sponsor(s)
We thank the IHME at the University of Washington for providing the microdata used in this study.
Jacqueline Seiglie was supported by Grant Number T32DK007028 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), by grant number 5KL2TR002542-03 (Harvard Catalyst), and by the Massachusetts General Hospital Endocrine Division John T. Potts Jr. Pilot Award Program. JBM is supported by NIDDK UM1DK078616 and National Heart, Lung and Blood Institute (NHLBI) R01HL151855.
Sources of information:
Directorio de Producción Científica
Scopus